GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Hold” from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given a consensus rating of “Hold” by the fourteen brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $4.7292.

GDRX has been the topic of a number of recent research reports. Wall Street Zen lowered GoodRx from a “buy” rating to a “hold” rating in a research report on Sunday. Morgan Stanley cut their price target on GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. JPMorgan Chase & Co. lowered their price objective on GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Finally, UBS Group restated a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th.

GoodRx Trading Down 0.4%

GDRX opened at $2.56 on Monday. GoodRx has a 1-year low of $2.47 and a 1-year high of $5.81. The stock has a market capitalization of $868.94 million, a PE ratio of 28.44, a PEG ratio of 0.97 and a beta of 1.45. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $2.75 and a two-hundred day moving average price of $3.65.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. GoodRx’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period last year, the company earned $0.08 earnings per share. As a group, equities analysts anticipate that GoodRx will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of GoodRx

A number of institutional investors have recently bought and sold shares of the business. Sugar Maple Asset Management LLC bought a new stake in shares of GoodRx during the 4th quarter valued at $83,000. Woodstock Corp bought a new stake in GoodRx in the fourth quarter valued at about $276,000. Wealth Enhancement Advisory Services LLC bought a new stake in GoodRx in the fourth quarter valued at about $65,000. PharVision Advisers LLC acquired a new position in GoodRx in the third quarter valued at about $172,000. Finally, Utah Retirement Systems boosted its holdings in GoodRx by 79.0% during the third quarter. Utah Retirement Systems now owns 292,212 shares of the company’s stock worth $1,236,000 after buying an additional 128,958 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.